Article

Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study

University of Texas at San Antonio, San Antonio, Texas, United States
Circulation (Impact Factor: 14.95). 10/2004; 110(10):1251-7. DOI: 10.1161/01.CIR.0000140762.04598.F9
Source: PubMed

ABSTRACT To assess the utility of clinical definitions of the metabolic syndrome (MetS) to identify individuals with increased cardiovascular risk, we examined the relation between the MetS, using both the National Cholesterol Education Program (NCEP) and the World Health Organization definitions, and all-cause and cardiovascular mortality in San Antonio Heart Study participants enrolled between 1984 and 1988.
Among 2815 participants, 25 to 64 years of age at enrollment, 509 met both criteria, 197 met NCEP criteria only, and 199 met WHO criteria only. Over an average of 12.7 years, 229 deaths occurred (117 from cardiovascular disease). Moreover, in the primary prevention population of 2372 participants (ie, those without diabetes or cardiovascular disease at baseline), 132 deaths occurred (50 from cardiovascular disease). In the primary prevention population, the only significant association adjusted for age, gender, and ethnic group was between NCEP-MetS and cardiovascular mortality (hazard ratio [HR], 2.01; 95% CI, 1.13-3.57). In the general population, all-cause mortality HRs were 1.47 (95% CI, 1.13-1.92) for NCEP-MetS and 1.27 (95% CI, 0.97-1.66) for WHO-MetS. Furthermore, for cardiovascular mortality, there was evidence that gender modified the predictive ability of the MetS. For women and men, respectively, HRs for NCEP-MetS were 4.65 (95% CI, 2.35-9.21) and 1.82 (95% CI, 1.14-2.91), whereas HRs for WHO-MetS were 2.83 (95% CI, 1.55-5.17) and 1.15 (95% CI, 0.72-1.86).
In summary, although both definitions were predictive in the general population, the simpler NCEP definition tended to be more predictive in lower-risk subjects.

Download full-text

Full-text

Available from: Kelly Hunt, Apr 20, 2015
0 Followers
 · 
102 Views
  • Source
    • "2. The unexpected complexity of the PCSK9-LDLR axis PCSK9 and LDLR are both under the regulation of sterol regulatory element binding proteins (SREBPs), being over-expressed under conditions of cellular cholesterol deficiency [9]. The most common cause of cellular cholesterol deficiency is treatment with a statin agent [10]. Thus, although those taking statins experience a large LDL-C reduction due to the over-expression of LDLR, it is likely that this effect is diminished by the concomitant increase in PCSK9 [11] [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulatory ligand that terminates the lifecycle of the low-density lipoprotein (LDL) receptor (LDLR) thus affecting plasma LDL-cholesterol (LDL-C) levels. Recent evidence shows that in addition to the straightforward mechanism of action, there are more complex interactions between PCSK9, LDLR and plasma lipoprotein levels, including: (a) the presence of both parallel and reciprocal regulation of surface LDLR and plasma PCSK9; (b) a correlation between PCSK9 and LDL-C levels dependent not only on the fact that PCSK9 removes hepatic LDLR, but also due to the fact that up to 40% of plasma PCSK9 is physically associated with LDL; and (c) an association between plasma PCSK9 production and the assembly and secretion of triglyceride-rich lipoproteins.
    Atherosclerosis 12/2014; 238(2). DOI:10.1016/j.atherosclerosis.2014.12.017 · 3.97 Impact Factor
  • Source
    • "Metabolic syndrome (MS) comprises a constellation of disturbances such as abdominal obesity, insulin resistance and dyslipidemia, which eventually result in hypertension. These disturbances put the patient at a high risk of developing type-2 diabetes and cardiovascular morbidities [3], [31]. The consumption of fructose, among others dietary changes, has been linked to the escalated incidence of MS [32], [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The metabolic syndrome (MS) is characterized by insulin resistance, dyslipidemia and hypertension. It is associated with increased risk of cardiovascular diseases and type-2 diabetes. Consumption of fructose is linked to increased prevalence of MS. Ursodeoxycholic acid (UDCA) is a steroid bile acid with antioxidant, anti-inflammatory activities and has been shown to improve insulin resistance. The current study aims to investigate the effect of UDCA (150 mg/kg) on MS induced in rats by fructose administration (10%) in drinking water for 12 weeks. The effects of UDCA were compared to fenofibrate (100 mg/kg), an agonist of PPAR-α receptors. Treatment with UDCA or fenofibrate started from the 6th week after fructose administration once daily. Fructose administration resulted in significant increase in body weight, elevations of blood glucose, serum insulin, cholesterol, triglycerides, advanced glycation end products (AGEs), uric acid levels, insulin resistance index and blood pressure compared to control rats. Moreover, fructose increased oxidative stress in aortic tissues indicated by significant increases of malondialdehyde (MDA), expression of iNOS and reduction of reduced glutathione (GSH) content. These disturbances were associated with decreased eNOS expression, increased infiltration of leukocytes and loss of aortic vascular elasticity. Treatment with UDCA successfully ameliorated the deleterious effects of fructose. The protective effect of UDCA could be attributed to its ability to decrease uric acid level, improve insulin resistance and diminish oxidative stress in vascular tissues. These results might support possible clinical application of UDCA in MS patients especially those present with liver diseases, taking into account its tolerability and safety. However, further investigations on human subjects are needed before the clinical application of UDCA for this indication.
    PLoS ONE 09/2014; 9(9):e106993. DOI:10.1371/journal.pone.0106993 · 3.23 Impact Factor
    • ". A number of studies have confirmed that the risks of developing CVD, and of both cardiovascular and all-causes of mortality, are increased by the presence of MS [7] [8] [9] [10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Background and aim Metabolic syndrome (MS) is becoming a serious global public health problem. The prevalence of MS differs in different population by using different definitions. Present study aimed to find out the prevalence and determinants of MS among newly diagnosed type 2 diabetes (NDT2D) according to different criteria. Subjects and methods This cross-sectional analytic study was conducted among 281 subjects selected purposively from the OPD of BIRDEM. Information on lifestyle factors and disease history were collected using a semi-structured questionnaire by face to face interview. The three definitions of MS used in this study are from the International Diabetes Federation (IDF), a modified version of the ATP III criteria for Asian populations (modified ATP III) and World Health Organization (WHO) criteria. Adjusted odds ratio and confidence limit were generated through logistic regression. Results The overall prevalence of metabolic syndrome among the study subjects according to modified ATPIII, WHO and IDF criteria were 79% (95% CI: 74.2-83.8), 81% (95% CI: 76.4-85.6) and 68% (95% CI: 62.6-73.5) respectively. The prevalence of metabolic syndrome among female were higher compared to males in all the criteria's. Female gender (OR = 5.93), family history of diabetes (OR = 1.92), overweight (OR = 6.2), and obesity (OR = 5.13) were found as important confounders associated with metabolic syndrome. Conclusion The prevalence of the metabolic syndrome among NDT2D is considerably higher in our population which may indicate considerable risk of cardiovascular diseases in future. Female gender, family history of diabetes, overweight and obesity are important confounders of MS in this population. Keywords Metabolic syndrome criteria; Newly diagnosed type 2 diabetes; Prevalence; Determinants; Bangladesh Corresponding author at: Sharmin Hossain, Department of Health Promotion and Health Education, Bangladesh University of Health Sciences (BUHS), 125/1, Darus Salam, Mirpur, Dhaka 1216, Bangladesh. Tel.: +880 1912028488.
    Diabetes and Metabolic Syndrome Clinical Research and Reviews 05/2014; 9(2). DOI:10.1016/j.dsx.2014.04.016
Show more